Tarsus Pharmaceuticals Inc
TARS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.72B
Close$
$-40.00
162.9% downside
Current Fair Value
162.9% downsideOvervalued by 162.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.72 Billion |
|---|---|
| Enterprise Value | $2.70 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.59 |
| Beta | 0.51 |
| Outstanding Shares | 42,956,973 |
Return
| Return on Equity | -13.83% |
|---|---|
| Return on Assets | -8.31% |
| Return on Invested Capital | -9.79% |
Valuation & Multiples
| P/E Ratio | -56.21 |
|---|---|
| PEG | 77.79 |
| Price to Sales | 5.3 |
| Price to Book Ratio | 7.95 |
| Enterprise Value to Revenue | 5.05 |
| Enterprise Value to EBIT | -63.1 |
| Enterprise Value to Net Income | -57 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
$149.90 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$170.02 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7633▲ 73.87% |
|---|---|
| Total Calls | 272,500▼ 18.36% |
| Total Puts | 208,000▲ 2436.59% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 105.51%▲ 2.12% |
|---|---|
| Total Invested | $3.17B▼ 12.19% |
| Investors Holding | 260▲ 9.00% |
ESG Score
No data
About Tarsus Pharmaceuticals Inc
20 employeesTarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a num...